GO:0032383 regulation of intracellular cholesterol transport: Cellular Lipid Trafficking Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032383 (regulation of intracellular cholesterol transport) describes any process that modulates the frequency, rate or extent of the directed movement of cholesterol within cells [2, 3].
• Cholesterol moves between organelles by both vesicular and non-vesicular mechanisms, including ER-Golgi contact sites and lysosome-to-PM routes [1, 2].
• Key regulators include SCAP-SREBP2, NPC1, SLC38A9, mTORC1, and natural molecules that modulate cholesterol trafficking [4, 5, 8].
• Dysregulation of intracellular cholesterol transport is linked to lysosomal storage disorders, immunogenic cell death, neurodegeneration, and metabolic disease [7, 8].
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect causal roles of transport regulators [1, 5].
• Methods such as live-cell imaging, organelle fractionation, and lipidomics are used to quantify cholesterol distribution and transport rates [1, 6].
Description
Regulation of intracellular cholesterol transport (GO:0032383) is a biological process that controls how cholesterol moves between organelles and membranes within a cell [2, 3]. Cholesterol is essential for membrane integrity, signaling, and hormone synthesis, but its accumulation in the wrong compartment can be toxic [6, 7]. Therefore, cells have evolved sophisticated regulatory mechanisms to maintain cholesterol homeostasis [2, 6]. This GO term captures the modulatory inputs that determine the frequency, rate, and extent of cholesterol's directed movement inside cells. Understanding this process is critical because defects in cholesterol trafficking underlie diseases ranging from Niemann-Pick type C to atherosclerosis and neurodegeneration [2, 7, 8]. Recent work has revealed that non-vesicular transport at ER-Golgi contact sites and lysosomal signaling complexes are central to this regulation [1, 8]. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0032383, its mechanisms, key genes, disease links, and experimental models.
regulation of intracellular cholesterol transport At A Glance
| GO ID | GO:0032383 |
|---|---|
| GO term | regulation of intracellular cholesterol transport |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulates the frequency, rate or extent of directed cholesterol movement within cells [2, 3] |
| Key regulators | SCAP-SREBP2, NPC1, SLC38A9, mTORC1, natural molecules [4, 5, 8] |
| Cellular locations | ER, Golgi, lysosomes, plasma membrane, mitochondria [1, 2] |
| Disease relevance | Lysosomal storage disorders, immunogenic cell death, neurodegeneration, metabolic disease [7, 8] |
What Is GO:0032383?
GO:0032383 is defined by QuickGO as any process that modulates the frequency, rate or extent of the directed movement of cholesterol within cells [2, 3]. In other words, it is the regulatory layer that governs how cholesterol is transported between organelles such as the endoplasmic reticulum (ER), Golgi, lysosomes, plasma membrane, and mitochondria [1, 2]. This term does not describe the transport itself but the control of that transport, including signaling pathways, lipid transfer proteins, and membrane contact sites that adjust cholesterol flux according to cellular needs [1, 6].
Why Is regulation of intracellular cholesterol transport Important in Cell Biology?
Regulation of intracellular cholesterol transport is fundamental to cellular physiology because cholesterol is both essential and potentially toxic. When this regulation fails, cholesterol accumulates in inappropriate compartments, triggering lysosomal damage, inflammasome activation, and cell death [5, 7]. Moreover, cholesterol trafficking influences membrane fluidity, signal transduction, and lipid droplet formation, impacting processes from immunity to neurodegeneration [2, 8]. Thus, understanding GO:0032383 provides mechanistic insight into a wide range of human diseases and identifies potential therapeutic targets [4, 7].
• Maintains cholesterol homeostasis and prevents lipotoxicity in organelles.
• Regulates lysosomal function and mTORC1 signaling via NPC1-SLC38A9.
• Controls inflammasome activation through SCAP-SREBP2 in macrophages.
• Implicated in Niemann-Pick type C disease and other lysosomal storage disorders [7, 8].
• Modulates immunogenic cell death triggered by lysosomal cholesterol accumulation.
• Influences atherosclerosis and cardiovascular disease through macrophage cholesterol handling [2, 5].
• Affects neuronal function and neurodegeneration via cholesterol trafficking defects.
• Targeted by natural molecules with therapeutic potential.
• Provides targets for CRISPR-based functional genomics [1, 5].
• Essential for membrane contact site biology and non-vesicular lipid transfer.
What Happens During regulation of intracellular cholesterol transport?
Cholesterol sensing and transcriptional control
In simple terms: Cells sense cholesterol levels and adjust production and uptake accordingly.
The SCAP-SREBP2 complex acts as a cholesterol sensor in the ER membrane. When cholesterol is low, SCAP escorts SREBP2 to the Golgi for activation, leading to transcription of cholesterol synthesis genes. This transcriptional regulation indirectly controls intracellular cholesterol transport by adjusting the pool of available cholesterol.
Non-vesicular transport at ER-Golgi contact sites
In simple terms: Cholesterol can hop between organelles at contact points without using vesicles.
Recent studies have shown that cholesterol is transferred between the ER and Golgi at membrane contact sites via non-vesicular mechanisms. This process regulates cellular cholesterol distribution and is mediated by lipid transfer proteins that bridge the two organelles. Disruption of these contact sites alters cholesterol trafficking and organelle function.
Lysosomal cholesterol export and signaling
In simple terms: Lysosomes release cholesterol and signal to the cell about nutrient status.
NPC1 is a lysosomal membrane protein that exports cholesterol from lysosomes. This export is coupled to mTORC1 activation via the SLC38A9-NPC1 complex, linking cholesterol trafficking to nutrient sensing. Defects in NPC1 cause cholesterol accumulation in lysosomes and trigger downstream pathologies [7, 8].
Vesicular trafficking pathways
In simple terms: Cholesterol can also be carried in vesicles between organelles.
In addition to non-vesicular routes, cholesterol moves via vesicular transport between the ER, Golgi, endosomes, and plasma membrane [2, 3]. This involves coat proteins, Rab GTPases, and SNAREs that regulate vesicle formation and fusion. The balance between vesicular and non-vesicular transport determines the overall distribution of cholesterol [1, 2].
Regulation by natural molecules and pharmacological agents
In simple terms: Certain natural compounds can tweak cholesterol transport.
Natural molecules such as phytosterols and polyphenols have been shown to modulate cholesterol transport and homeostasis. These compounds can influence ABC transporters, NPC1, and other trafficking proteins, offering potential therapeutic avenues. Their effects on GO:0032383 are an active area of research.
Key Genes Involved in GO:0032383 regulation of intracellular cholesterol transport
The following genes and proteins are central to the regulation of intracellular cholesterol transport (GO:0032383), based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SCAP | Cholesterol sensor that escorts SREBP2 to Golgi | Links cholesterol sensing to inflammasome activation |
| SREBP2 | Transcription factor controlling cholesterol synthesis genes | Master regulator of cholesterol homeostasis |
| NPC1 | Lysosomal cholesterol export protein | Mutations cause Niemann-Pick type C disease [7, 8] |
| SLC38A9 | Lysosomal arginine sensor that interacts with NPC1 | Connects cholesterol to mTORC1 signaling |
| mTORC1 | Kinase complex activated by lysosomal cholesterol | Integrates nutrient and cholesterol signals |
| ABCA1 | Mediates cholesterol efflux to apoA-I | Target for natural molecules modulating transport |
| ABCG1 | Transfers cholesterol to HDL | Involved in macrophage cholesterol efflux |
| Caveolin-1 | Structural protein in caveolae that transports cholesterol | Regulates plasma membrane cholesterol distribution |
| Rab7 | Late endosome/lysosome trafficking GTPase | Controls vesicular cholesterol transport |
| Rab9 | Late endosome to Golgi transport | Implicated in cholesterol trafficking |
| OSBP | Oxysterol-binding protein at ER-Golgi contact sites | Mediates non-vesicular cholesterol transport |
| CERT | Ceramide transfer protein at ER-Golgi contacts | Coordinates lipid transfer with cholesterol |
| VAP-A | ER membrane protein at contact sites | Scaffolds lipid transfer proteins |
| VAP-B | ER membrane protein at contact sites | Scaffolds lipid transfer proteins |
| NPC2 | Lysosomal cholesterol binding protein | Works with NPC1 in cholesterol export |
| SREBP1 | Transcription factor for fatty acid synthesis | Cross-talk with cholesterol regulation |
| HMGCR | Rate-limiting enzyme in cholesterol synthesis | Target of statins, affects transport pool |
How Is regulation of intracellular cholesterol transport Regulated?
Regulation of intracellular cholesterol transport is controlled at multiple levels. The SCAP-SREBP2 pathway senses ER cholesterol and adjusts transcription of synthesis and uptake genes. Lysosomal cholesterol activates mTORC1 via the SLC38A9-NPC1 complex, linking transport to nutrient signaling. Additionally, natural molecules can modulate transport proteins such as ABCA1 and NPC1. Membrane contact sites between ER and Golgi are dynamically regulated by lipid transfer proteins like OSBP and CERT. These layers of regulation ensure cholesterol is delivered to the right place at the right time [2, 6].
regulation of intracellular cholesterol transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NPC1 | Niemann-Pick type C disease [7, 8] | NPC1 knockout HeLa or patient fibroblasts |
| SCAP | Inflammasome activation in macrophages | SCAP knockout macrophages |
| SLC38A9 | mTORC1 signaling and lysosomal cholesterol sensing | SLC38A9 knockout HEK293T cells |
| ABCA1 | Atherosclerosis and cholesterol efflux | ABCA1 knockout macrophages |
| OSBP | ER-Golgi cholesterol transport | OSBP knockout HeLa cells |
Niemann-Pick type C disease and lysosomal storage disorders
Mutations in NPC1 or NPC2 cause Niemann-Pick type C disease, characterized by lysosomal cholesterol accumulation [7, 8]. This leads to neurodegeneration, hepatosplenomegaly, and early death. The disease highlights the critical role of GO:0032383 in human health.
Immunogenic cell death and inflammation
Lysosomal damage due to cholesterol accumulation triggers immunogenic cell death, linking cholesterol transport to anti-tumor immunity. SCAP-SREBP2 integrates cholesterol biosynthetic signaling with NLRP3 inflammasome activation in macrophages, connecting GO:0032383 to inflammation.
Atherosclerosis and cardiovascular disease
Defective cholesterol efflux from macrophages leads to foam cell formation and atherosclerosis. Regulation of intracellular cholesterol transport is therefore central to cardiovascular pathology [2, 4].
Neurodegeneration
Cholesterol trafficking defects impair neuronal function and are implicated in Alzheimer's disease and other neurodegenerative conditions. Proper regulation of intracellular cholesterol transport is essential for brain health [2, 6].
From regulation of intracellular cholesterol transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NPC1 alter lysosomal cholesterol export? | NPC1 knockout cell line [7, 8] |
| Does a point mutation in SCAP affect SREBP2 processing? | SCAP point-mutation knock-in |
| Can we tag endogenous OSBP to track ER-Golgi contact sites? | OSBP knock-in with fluorescent tag |
| Does overexpression of ABCA1 increase cholesterol efflux? | ABCA1 overexpression stable line |
| Which genes regulate cholesterol transport under lipid stress? | Genome-wide CRISPR knockout library screening [1, 5] |
| Does SLC38A9 mediate cholesterol-dependent mTORC1 activation? | SLC38A9 knockout and rescue |
How to Study the regulation of intracellular cholesterol transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Filipin staining | Free cholesterol distribution | Visualize lysosomal cholesterol accumulation |
| Live-cell imaging with GFP-OSBP | ER-Golgi contact site dynamics | Study non-vesicular transport |
| Subcellular fractionation + MS | Cholesterol content per organelle | Quantify transport defects |
| CRISPR knockout screen | Genes affecting cholesterol transport | Identify novel regulators [1, 5] |
| mTORC1 activity assay | Downstream signaling | Link cholesterol to nutrient sensing |
| Cholesterol efflux assay | ABCA1-mediated efflux | Study atherosclerosis models |
| Immunofluorescence | Protein localization | Validate organelle markers |
| Lipidomics | Global lipid species | Assess broader metabolic impact |
Live-cell imaging of cholesterol probes
Fluorescent cholesterol analogs such as filipin or GFP-tagged cholesterol-binding domains allow real-time visualization of cholesterol distribution and transport between organelles [1, 6]. This method is essential for studying dynamic regulation of GO:0032383.
Organelle fractionation and lipidomics
Subcellular fractionation followed by mass spectrometry quantifies cholesterol content in ER, Golgi, lysosomes, and plasma membrane [2, 6]. This provides a snapshot of transport regulation under different conditions.
Genetic screens and CRISPR libraries
Genome-wide CRISPR knockout screens identify genes that regulate intracellular cholesterol transport [1, 5]. Hits can be validated with targeted knockouts and point mutations.
Biochemical transport assays
In vitro assays using isolated organelles or reconstituted systems measure cholesterol transfer rates between membranes [1, 2]. These assays help dissect non-vesicular versus vesicular transport mechanisms.
How CRISPR Can Be Used to Study GO:0032383 regulation of intracellular cholesterol transport
Knockout
CRISPR knockout of genes such as NPC1, SCAP, or OSBP is used to determine their causal role in regulating intracellular cholesterol transport [1, 5, 7]. Knockout cell lines show altered cholesterol distribution and downstream signaling [7, 8].
Point Mutation
Point mutations can mimic disease-associated variants in genes like NPC1 or SCAP, allowing precise dissection of regulatory mechanisms [5, 7]. For example, a point mutation in SCAP can disrupt cholesterol sensing without affecting protein stability.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) into endogenous loci such as OSBP enables real-time tracking of protein dynamics at contact sites. This approach preserves endogenous regulation.
Overexpression
Overexpression of genes like ABCA1 or NPC1 can enhance cholesterol transport and rescue defects [2, 8]. This is useful for gain-of-function studies and therapeutic target validation.
How EDITGENE Supports regulation of intracellular cholesterol transport Research
Researchers studying regulation of intracellular cholesterol transport-related genes often need to determine whether a candidate gene is causally involved in cholesterol trafficking, and whether specific mutations alter its regulatory function. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for regulation of intracellular cholesterol transport research.
Frequently Asked Questions About regulation of intracellular cholesterol transport
What is GO:0032383?
GO:0032383 is the Gene Ontology term for regulation of intracellular cholesterol transport, defined as any process that modulates the frequency, rate or extent of the directed movement of cholesterol within cells [2, 3].
What genes are involved in regulation of intracellular cholesterol transport?
Key genes include SCAP, SREBP2, NPC1, SLC38A9, mTORC1, ABCA1, ABCG1, OSBP, and CERT, among others [1, 2, 5, 8].
How is intracellular cholesterol transport regulated?
It is regulated by cholesterol sensing via SCAP-SREBP2, lysosomal signaling through NPC1-SLC38A9-mTORC1, and non-vesicular transfer at ER-Golgi contact sites [1, 5, 8].
What diseases are linked to defective cholesterol transport?
Niemann-Pick type C disease, atherosclerosis, neurodegeneration, and immunogenic cell death are linked to defects in intracellular cholesterol transport [2, 7, 8].
What methods are used to study regulation of intracellular cholesterol transport?
Methods include live-cell imaging with fluorescent cholesterol probes, organelle fractionation, lipidomics, and CRISPR screens [1, 2, 6].
Can CRISPR be used to study cholesterol transport?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect gene function in cholesterol transport [1, 5, 7].
What is the role of NPC1 in cholesterol transport?
NPC1 exports cholesterol from lysosomes; mutations cause Niemann-Pick type C disease and trigger lysosomal cholesterol accumulation [7, 8].
How does mTORC1 sense cholesterol?
Lysosomal cholesterol activates mTORC1 via the SLC38A9-NPC1 signaling complex.
What are ER-Golgi contact sites in cholesterol transport?
They are membrane contact sites where non-vesicular cholesterol transfer occurs, mediated by proteins like OSBP and CERT.
Why is regulation of intracellular cholesterol transport important for drug discovery?
It is a target for natural molecules and synthetic drugs aimed at treating metabolic, cardiovascular, and neurodegenerative diseases [4, 7].
Conclusion
Regulation of intracellular cholesterol transport (GO:0032383) is a critical biological process that ensures cholesterol is delivered to the right organelle at the right time [2, 3]. Dysregulation of this process leads to severe diseases, including Niemann-Pick type C, atherosclerosis, and neurodegeneration [7, 8]. Recent advances have uncovered key roles for SCAP-SREBP2, NPC1-SLC38A9-mTORC1, and ER-Golgi contact sites in this regulation [1, 5, 8]. CRISPR-based models are indispensable for dissecting these mechanisms and identifying therapeutic targets [1, 5]. EDITGENE offers comprehensive services to accelerate research in this field.
References
- 1. Naito T et al.. 2023. Regulation of cellular cholesterol distribution via non-vesicular lipid transport at ER-Golgi contact sites.. Nat Commun 14(1):5867 PMID: 37735529
- 2. Soccio RE et al.. 2004. Intracellular cholesterol transport.. Arterioscler Thromb Vasc Biol 24(7):1150-60 PMID: 15130918
- 3. Fielding CJ et al.. 1997. Intracellular cholesterol transport.. J Lipid Res 38(8):1503-21 PMID: 9300773
- 4. Tan M et al.. 2021. Recent developments in the regulation of cholesterol transport by natural molecules.. Phytother Res 35(10):5623-5633 PMID: 34327759
- 5. Guo C et al.. 2018. Cholesterol Homeostatic Regulator SCAP-SREBP2 Integrates NLRP3 Inflammasome Activation and Cholesterol Biosynthetic Signaling in Macrophages.. Immunity 49(5):842-856.e7 PMID: 30366764
- 6. Liscum L et al.. 1992. Intracellular cholesterol transport.. J Lipid Res 33(9):1239-54 PMID: 1402394
- 7. Alvarez-Valadez K et al.. 2025. Lysosomal damage due to cholesterol accumulation triggers immunogenic cell death.. Autophagy 21(5):934-956 PMID: 39663580
- 8. Castellano BM et al.. 2017. Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling complex.. Science 355(6331):1306-1311 PMID: 28336668
